ArticleNature biotechnology2026

Comprehensive profiling of clinically approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing.

Mehlam Saifudeen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.